ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - mitu müeloomit - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. koos bortezomib, talidomiid ja deksametasooni raviks täiskasvanud patsientidel, kellel on äsja diagnoositud hulgimüeloom, kes vastavad tüvirakkude autoloogne siirdamine. koos lenalidomide ja deksametasoon või bortezomib ja deksametasooni, raviks täiskasvanud patsientidel, kellel on hulgimüeloom, kes on saanud vähemalt ühe eelneva ravi. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. kui monotherapy raviks täiskasvanud patsientidel, kellel on taastekkinud ja tulekindlad hulgimüeloom, kelle eelnev ravi sisaldas proteasome inhibiitor ja immuunmoduleerivad agent ja kes on näidanud haiguse progresseerumise viimasel ravi. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

krka, d.d., novo mesto - deksametasoon - tablett - 8mg 50tk; 8mg 20tk; 8mg 100tk; 8mg 60tk; 8mg 10tk; 8mg 30tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

first pharma oÜ - deksametasoon - tablett - 4mg 28tk; 4mg 30tk; 4mg 50tk; 4mg 56tk; 4mg 60tk; 4mg 10tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

krka, d.d., novo mesto - deksametasoon - tablett - 4mg 100tk; 4mg 28tk; 4mg 10tk; 4mg 50tk; 4mg 56tk; 4mg 60tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

krka d.d. novo mesto - deksametasoon - süstelahus - 4mg 1ml 1ml 25tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

kalceks as - deksametasoon - süste-/infusioonilahus - 4mg 1ml 2ml 5tk; 4mg 1ml 2ml 10tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

lex ano uab - deksametasoon - tablett - 4mg 20tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

fresenius kabi polska sp. z o.o. - deksametasoon - süstelahus - 4mg 1ml 2ml 50tk; 4mg 1ml 1ml 10tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 4mg 28tk; 4mg 56tk; 4mg 100tk